Everything below concerns clinical endpoint. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-02. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Taha Othman Ishaq (or Osman), a lawyer and member of the FFC negotiating committee, declined his nomination by the FFC to the Sovereignty Council on the grounds that the FFC alliance had earlier agreed that members of the negotiating committee should not become members of the Sovereignty Council. Raja Nicola was the civilian member of the Sovereignty Council mutually chosen by the FFC and TMC. The choice of Nicola, as a member of the Sudanese Copt community, is seen as a symbol of respect for diversity, in particular to Sudanese Christians. On 4 February 2021, al-Burhan issued a decree to add three new members to the Council. The new members are Sudanese Revolutionary Front leader El Hadi Idris Yahya, Sudan People's Liberation Movement-North leader Malik Agar, and Sudan Liberation Movement for Justice-Karbino leader El Tahrir Abubakr Hajar.
Gouy-Chapman theory describes the effect of a static surface charge on a surface's potential. "Gouy suggested that interfacial potential at the charged surface could be attributed to the presence of a number of ions of given charge attached to its surface, and to an equal number of ions of opposite charge in the solution." A positive surface charge will form a double layer, since negative ions in solution tend to balance the positive surface charge. Counter ions are not rigidly held, but tend to diffuse into the liquid phase until the counter potential set up by their departure restricts this tendency. The kinetic energy of the counter ions will, in part, affect the thickness of the resulting diffuse double layer. The relation between C, the counter ion concentration at the surface, and
=== Activation by protease and metalloprotease === Plasmin and a member of matrix metalloproteinases (MMP) play a key role in promoting tumor invasion and tissue remodeling by inducing proteolysis of several ECM components. The TGF-β activation process involves the release of the LLC from the matrix, followed by further proteolysis of the LAP to release TGF-β to its receptors. MMP-9 and MMP-2 are known to cleave latent TGF-β. The LAP complex contains a protease-sensitive hinge region which can be the potential target for this liberation of TGF-β. Despite the fact that MMPs have been proven to play a key role in activating TGF-β, mice with mutations in MMP-9 and MMP-2 genes can still activate TGF-β and do not show any TGF-β deficiency phenotypes, this may reflect redundancy among the activating enzymes suggesting that other unknown proteases might be involved.
Sources: en.wikipedia.org
forward genetics An experimental approach in molecular genetics in which a researcher starts with a specific known phenotype and attempts to determine the genetic basis of that phenotype by any of a variety of laboratory techniques, commonly by inducing random mutations in the organism's genome and then screening for changes in the phenotype of interest. Observed phenotypic changes are assumed to have resulted from the mutation(s) present in the screened sample, which can then be mapped to specific genomic loci and ultimately to one or more specific candidate genes. This methodology contrasts with reverse genetics, in which a specific gene or its gene product is individually manipulated in order to identify the gene's function.
Morphine ascorbate and other salts such as the tannate, citrate, and acetate, phosphate, valerate and others may be present in poppy tea depending on the method of preparation. The salts listed by the United States Drug Enforcement Administration for reporting purposes, in addition to a few others, are as follows:
=== Australia === The following programs of study have currently been approved by the Dental Board of Australia for the profession of dental prosthetics. On successful completion of the selected courses, individuals are required to register with the Australian Health Practitioner Regulation Agency to practice legally as a dental prosthetist.
A particular focus of many US media stories is the long-running coverage of the case of Brett Chidester, a 17-year-old Delaware student who committed suicide in January 2006 by carbon monoxide poisoning. Reportedly, some months before this, Brett's mother Kathleen Chidester had learned about his salvia use and questioned him about it. Brett said that he had ceased his experimentation, but his parents did not believe that he was telling the truth. They have instead argued that salvia-induced depression was largely to blame for his death. Some of Brett's earlier writings about his salvia experiences have been used to suggest that it made him think "existence in general is pointless." Some media stories have referred to these earlier written experience reports as if they were part of Brett's suicide note. A law was soon passed in Delaware classifying the herb as a Schedule I controlled substance in that state. This legislation was nicknamed Brett's law (formally referred to as Senate bill 259). Although the Chidester story has been given continued exposure by US media, there has not been anywhere else, either before or since this controversial incident, any other reported cases involving or alleging Salvia divinorum as a serious factor in suicide, overdose, accidental, or any other kind of death.
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.